BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 22581165)

  • 21. Pemetrexed induced thymidylate synthase inhibition in non-small cell lung cancer patients: a pilot study with 3'-deoxy-3'-[¹⁸F]fluorothymidine positron emission tomography.
    Frings V; van der Veldt AA; Boellaard R; Herder GJ; Giovannetti E; Honeywell R; Peters GJ; Thunnissen E; Hoekstra OS; Smit EF
    PLoS One; 2013; 8(5):e63705. PubMed ID: 23717468
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Thymidine phosphorylase influences [(18)F]fluorothymidine uptake in cancer cells and patients with non-small cell lung cancer.
    Lee SJ; Yeo JS; Lee HJ; Lee EJ; Kim SY; Jang SJ; Lee JJ; Ryu JS; Moon DH
    Eur J Nucl Med Mol Imaging; 2014 Jul; 41(7):1327-35. PubMed ID: 24562648
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Can 3'-deoxy-3'-(18)F-fluorothymidine or 2'-deoxy-2'-(18)F-fluoro-d-glucose PET/CT better assess response after 3-weeks treatment by epidermal growth factor receptor kinase inhibitor, in non-small lung cancer patients? Preliminary results.
    Bhoil A; Singh B; Singh N; Kashyap R; Watts A; Sarika S; Mittal BR
    Hell J Nucl Med; 2014; 17(2):90-6. PubMed ID: 24997081
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vivo imaging of cell proliferation enables the detection of the extent of experimental rheumatoid arthritis by 3'-deoxy-3'-18f-fluorothymidine and small-animal PET.
    Fuchs K; Kohlhofer U; Quintanilla-Martinez L; Lamparter D; Kötter I; Reischl G; Röcken M; Pichler BJ; Kneilling M
    J Nucl Med; 2013 Jan; 54(1):151-8. PubMed ID: 23213198
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interobserver agreement of qualitative analysis and tumor delineation of 18F-fluoromisonidazole and 3'-deoxy-3'-18F-fluorothymidine PET images in lung cancer.
    Thureau S; Chaumet-Riffaud P; Modzelewski R; Fernandez P; Tessonnier L; Vervueren L; Cachin F; Berriolo-Riedinger A; Olivier P; Kolesnikov-Gauthier H; Blagosklonov O; Bridji B; Devillers A; Collombier L; Courbon F; Gremillet E; Houzard C; Caignon JM; Roux J; Aide N; Brenot-Rossi I; Doyeux K; Dubray B; Vera P
    J Nucl Med; 2013 Sep; 54(9):1543-50. PubMed ID: 23918733
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Parametric Method Performance for Dynamic 3'-Deoxy-3'-
    Kramer GM; Frings V; Heijtel D; Smit EF; Hoekstra OS; Boellaard R;
    J Nucl Med; 2017 Jun; 58(6):920-925. PubMed ID: 28572289
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Both high intratumoral microvessel density determined using CD105 antibody and elevated plasma levels of CD105 in colorectal cancer patients correlate with poor prognosis.
    Li C; Gardy R; Seon BK; Duff SE; Abdalla S; Renehan A; O'Dwyer ST; Haboubi N; Kumar S
    Br J Cancer; 2003 May; 88(9):1424-31. PubMed ID: 12778073
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of Platinum-Based Chemoradiotherapy on Cellular Proliferation in Bone Marrow and Spleen, Estimated by (18)F-FLT PET/CT in Patients with Locally Advanced Non-Small Cell Lung Cancer.
    Leimgruber A; Möller A; Everitt SJ; Chabrot M; Ball DL; Solomon B; MacManus M; Hicks RJ
    J Nucl Med; 2014 Jul; 55(7):1075-80. PubMed ID: 24868108
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of angiogenesis in non-small cell lung cancer: comparison between anti-CD34 antibody and anti-CD105 antibody.
    Tanaka F; Otake Y; Yanagihara K; Kawano Y; Miyahara R; Li M; Yamada T; Hanaoka N; Inui K; Wada H
    Clin Cancer Res; 2001 Nov; 7(11):3410-5. PubMed ID: 11705856
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Microvessel density assessment in benign and malignant endometrial changes.
    Czekierdowski A; Czekierdowska S; Czuba B; Cnota W; Sodowski K; Kotarski J; Zwirska-Korczala K
    J Physiol Pharmacol; 2008 Sep; 59 Suppl 4():45-51. PubMed ID: 18955753
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Early detection of erlotinib treatment response in NSCLC by 3'-deoxy-3'-[F]-fluoro-L-thymidine ([F]FLT) positron emission tomography (PET).
    Ullrich RT; Zander T; Neumaier B; Koker M; Shimamura T; Waerzeggers Y; Borgman CL; Tawadros S; Li H; Sos ML; Backes H; Shapiro GI; Wolf J; Jacobs AH; Thomas RK; Winkeler A
    PLoS One; 2008; 3(12):e3908. PubMed ID: 19079597
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pre-clinical validation of orthotopically-implanted pulmonary tumor by imaging with 18F-fluorothymidine-positron emission tomography/computed tomography.
    Fushiki H; Miyoshi S; Noda A; Murakami Y; Sasaki H; Jitsuoka M; Mitsuoka K; Matsunari I; Nishimura S
    Anticancer Res; 2013 Nov; 33(11):4741-9. PubMed ID: 24222108
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of 3'-deoxy-3'-[¹⁸F]fluorothymidine positron emission tomography (FLT PET) and FDG PET/CT for the detection and characterization of pancreatic tumours.
    Herrmann K; Erkan M; Dobritz M; Schuster T; Siveke JT; Beer AJ; Wester HJ; Schmid RM; Friess H; Schwaiger M; Kleeff J; Buck AK
    Eur J Nucl Med Mol Imaging; 2012 May; 39(5):846-51. PubMed ID: 22278320
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of the diagnostic value of 3-deoxy-3-18F-fluorothymidine and 18F-fluorodeoxyglucose positron emission tomography/computed tomography in the assessment of regional lymph node in thoracic esophageal squamous cell carcinoma: a pilot study.
    Han D; Yu J; Zhong X; Fu Z; Mu D; Zhang B; Xu G; Yang W; Zhao S
    Dis Esophagus; 2012 Jul; 25(5):416-26. PubMed ID: 21951837
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Early reduction in tumour [18F]fluorothymidine (FLT) uptake in patients with non-small cell lung cancer (NSCLC) treated with radiotherapy alone.
    Trigonis I; Koh PK; Taylor B; Tamal M; Ryder D; Earl M; Anton-Rodriguez J; Haslett K; Young H; Faivre-Finn C; Blackhall F; Jackson A; Asselin MC
    Eur J Nucl Med Mol Imaging; 2014 Apr; 41(4):682-93. PubMed ID: 24504503
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predictive value of microvascular density for response to anlotinib in advanced NSCLC.
    Liu D; Ding G
    Medicine (Baltimore); 2022 Jan; 101(3):e28647. PubMed ID: 35060554
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A pilot study to evaluate 3'-deoxy-3'-18F-fluorothymidine pet for initial and early response imaging in mantle cell lymphoma.
    Herrmann K; Buck AK; Schuster T; Rudelius M; Wester HJ; Graf N; Scheuerer C; Peschel C; Schwaiger M; Dechow T; Keller U
    J Nucl Med; 2011 Dec; 52(12):1898-902. PubMed ID: 22065875
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Density of microvessels positive for CD105 (endoglin) is related to prognosis in meningiomas.
    Barresi V; Cerasoli S; Vitarelli E; Tuccari G
    Acta Neuropathol; 2007 Aug; 114(2):147-56. PubMed ID: 17594108
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic significance of microvessel density determined by an anti-CD105/endoglin monoclonal antibody in astrocytic tumors: comparison with an anti-CD31 monoclonal antibody.
    Yao Y; Kubota T; Takeuchi H; Sato K
    Neuropathology; 2005 Sep; 25(3):201-6. PubMed ID: 16193836
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Correlation between CD105 expression and postoperative recurrence and metastasis of hepatocellular carcinoma.
    Yang LY; Lu WQ; Huang GW; Wang W
    BMC Cancer; 2006 May; 6():110. PubMed ID: 16650286
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.